ArticleProstate cancer and prostatic diseases2005
A potential novel marker for human prostate cancer: voltage-gated sodium channel expression in vivo.
Article in Prostate cancer and prostatic diseases, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed.
- TMEM16A in prostate cancer: mechanistic insights and therapeutic implications.Cancer cell international · 2025Review
- Sodium channels in non-excitable cells: powerful actions and therapeutic targets beyond Hodgkin and Huxley.Trends in cell biology · 2025Review
- Biological Activity of Biomarkers Associated With Metastasis in Osteosarcoma Cell Lines.Cancer medicine · 2025Article
- The Problem of Diagnosing Prostate Cancer-The Promise of Ion Channels as Novel Biomarkers of Disease!Bioelectricity · 2025Article
- Electrical excitability of cancer cells-CELEX model updated.Cancer metastasis reviews · 2024Review
- Voltage-gated sodium channels in cancers.Biomarker research · 2024Review
- Review
- Ranolazine: a potential anti-metastatic drug targeting voltage-gated sodium channels.British journal of cancer · 2024Review
- Lidocaine Inhibits Rat Prostate Cancer Cell Invasiveness and Voltage-Gated Sodium Channel Expression in Plasma Membrane.The Journal of membrane biology · 2024Article
- Therapeutic targeting of voltage-gated sodium channel NaFrontiers in pharmacology · 2024Review
- Voltage-Gated Sodium Channel NaCancers · 2023Article
- Sodium channels and the ionic microenvironment of breast tumours.The Journal of physiology · 2023Article
- From HDAC to Voltage-Gated Ion Channels: What's Next? The Long Road of Antiepileptic Drugs Repositioning in Cancer.Cancers · 2022Review
- Non-canonical endogenous expression of voltage-gated sodium channel NaThe Journal of physiology · 2022Article
- Genomic analyses reveal SCN7A is associated with the prognosis of esophageal squamous cell carcinoma.Esophagus : official journal of the Japan Esophageal Society · 2022Article
- Comprehensive Analysis of the Oncogenic, Genomic Alteration, and Immunological Landscape of Cation-Chloride Cotransporters in Pan-Cancer.Frontiers in oncology · 2022Article
- Neonatal Nav1.5 Protein Expression in Human Colorectal Cancer: Immunohistochemical Characterization and Clinical Evaluation.Cancers · 2021Article
- From Poison to Promise: The Evolution of Tetrodotoxin and Its Potential as a Therapeutic.Toxins · 2021Review
- Pharmacological and nutritional targeting of voltage-gated sodium channels in the treatment of cancers.iScience · 2021Review
- Imaging the transmembrane and transendothelial sodium gradients in gliomas.Scientific reports · 2021Article
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Functional expression of voltage-gated sodium channel alpha-subunits (VGSCalphas), specifically Nav1.7, is associated with strong metastatic potential in prostate cancer (CaP) in vitro. Furthermore, VGSC activity in vitro directly potentiates processes integral to metastasis. To investigate VGSCalpha expression in CaP in vivo, immunohistochemistry and real-time PCR were performed on human prostate biopsies (n>20). VGSCalpha immunostaining was evident in prostatic tissues and markedly stronger in CaP vs non-CaP patients. Importantly, RT-PCRs identified Nav1.7 as the VGSCalpha most strikingly upregulated (approximately 20-fold) in CaP, and the resultant receiver-operating characteristics curve demonstrated high diagnostic efficacy for the disease. It is concluded that VGSCalpha expression increases significantly in CaP in vivo and that Nav1.7 is a potential functional diagnostic marker.
Indexed as
Identifiers
16088330What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.